AbCellera Biologics (ABCL) Non Operating Income (2020 - 2026)

AbCellera Biologics' Non Operating Income history runs 7 years deep, the most recent figure standing at $8.0 million for Q1 2026.

• Quarterly Non Operating Income fell 17.51% year-over-year to $8.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $37.8 million (down 66.21% YoY) and the FY2025 annual result came in at $39.5 million, down 65.46% from the prior year.
• Non Operating Income was $8.0 million for Q1 2026 at AbCellera Biologics, down from $9.1 million in the prior quarter.
• Across five years, Non Operating Income topped out at $45.3 million in Q2 2024 and bottomed at $1.5 million in Q2 2022.
• A 5-year average of $14.6 million and a median of $12.1 million in 2024 frame the typical range for Non Operating Income.
• Annual changes were most pronounced in 2023 — Non Operating Income surged 786.42% — and 2025, when it plunged 75.8%.
• AbCellera Biologics' Non Operating Income stood at $6.4 million in 2022, then jumped by 174.13% to $17.5 million in 2023, then jumped by 48.56% to $25.9 million in 2024, then tumbled by 64.97% to $9.1 million in 2025, then retreated by 12.12% to $8.0 million in 2026.
• Business Quant data shows ABCL's Non Operating Income at $8.0 million in Q1 2026, $9.1 million in Q4 2025, and $7.5 million in Q3 2025.